Yosef Uziel

Tel Aviv, TA, IL

Clinical Trials:Currently Recruiting for 2 Trials

Expertise in

conditions

Tel Aviv, TA, IL

Overview

Yosef Uziel practices in Tel Aviv, Israel. Mr. Uziel is highly rated in 21 conditions, according to our data. His top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Scleroderma, Systemic Sclerosis (SSc), Familial Mediterranean Fever, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 122 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Tel Aviv, TA, Israel

Other Locations

Kfar Saba, M, Israel

Petah Tiqwa, M, Israel

Jaffa, TA, Israel

Ramat Aviv, TA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)

Enrollment Status: Recruiting

Publish Date: February 10, 2026

Intervention Type: Drug

Study Drug: Baricitnib

Study Phase: Phase 3

Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.

Enrollment Status: Recruiting

Publish Date: February 10, 2026

Intervention Type: Drug

Study Drug: Baricitinib

Study Phase: Phase 3

A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)

Enrollment Status: Completed

Publish Date: October 07, 2022

Intervention Type: Drug

Study Drug: Baricitnib

Study Phase: Phase 3

View 1 Less Clinical Trial

121 Total Publications

How Physicians Manage Colchicine-Resistant FMF: Insights from a Multinational Survey in High-Prevalence Countries.

Journal: The Journal of rheumatology

Published: January 15, 2026

View All 121 Publications

Frequently Asked Questions about Yosef Uziel

Is Yosef Uziel a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Yosef Uziel is classified as an Elite expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yosef Uziel participate in research or clinical trials?

Yes. Yosef Uziel has published 121 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Yosef Uziel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Uziel's expertise for a condition

ConditionClose